MethylGene Alternatives & Competitors

12 companies similar to MethylGene — Harnessing Innovation to Develop Next-Generation Cancer Therapies

KeifeRx

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...

7 Series A $6.00M

Mclean, United States

Biopharma Biotechnology +1

ORIC Pharmaceuticals Inc.

Overcoming Resistance In Cancer

119 Post-IPO Equity $408.00M

South San Francisco, Unit...

Biopharma Biotechnology +3

Onconova Therapeutics

Onconova is focused on discovering and developing novel products for patients with cancer.

20 Post-IPO Equity $177.92M

Newtown, United States

Biopharma Biotechnology +1

Ambit

Driving breakthroughs in cancer and inflammatory disease treatment through pioneering kina...

197 Venture round $215.73M

Biopharma Biotechnology +1

Track all MethylGene competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Arno Therapeutics Inc (ARNI)

3 Post-IPO Equity $61.40M

Biopharma Biotechnology

SELLAS Life Sciences Group, Inc.

A late-stage clinical biopharmaceutical company focused on developing novel therapies for...

18 Post-IPO Equity $101.70M

New York, United States

Biopharma Biotechnology

Ascentage Pharma

134 Post-IPO Equity $740.50M

China

Biopharma Biotechnology +1

MEI Pharma

Committed to the development of novel, best-in-class, cancer therapies intended to provide...

121 Post-IPO Equity $160.36M

San Diego, United States

Biopharma Biotechnology

Day One Biopharmaceuticals

Cancer drug development comes of age.

190 Post-IPO Equity $687.50M

Brisbane, United States

Biopharma Biotechnology +2

Apexigen

Creating Transformative Immunotherapies for Patients with Cancer

11 Post-IPO Equity $175.80M

San Carlos, United States

Biopharma Biotechnology +2

Agennix

Crafting novel therapies to enhance the length and quality of life for seriously ill patie...

Venture round $111.00M

Biopharma Biotechnology +2

Raptor Pharmaceuticals

Embarking on a journey to better health through innovative biotechnology solutions for bra...

Post-IPO Equity $222.89M

Biopharma Biotechnology +1

About MethylGene

MethylGene is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics primarily targeting cancer. Founded in 1997, it trades on the public market under the symbol TSX:MYG. The company's product portfolio includes MGCD265, an oral, multi-targeted kinase in...

Business keywords

Biopharmaceutical Company, Clinical Stage, Cancer Therapeutics, Kinase Inhibitors, HDAC Inhibitors, Oncology, Pharmaceutical Research, Clinical Trials, Drug Development, Neurodegenerative Diseases, Publicly Traded, Oncology Treatments, MethylGene Inc., Taiho Pharmaceutical Co. Ltd.

Frequently Asked Questions

Companies similar to MethylGene include KeifeRx, ORIC Pharmaceuticals Inc., Onconova Therapeutics, Ambit, Arno Therapeutics Inc (ARNI). They work in Biopharma and Biotechnology and share MethylGene's focus on clinical trials, drug development and oncology.

Bounce Watch lists 12 companies that share MethylGene's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches MethylGene and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

MethylGene Profile KeifeRx Alternatives ORIC Pharmaceuticals Inc. Alternatives Onconova Therapeutics Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at MethylGene on 19 Jun 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.